Becton, Dickinson and Company (NYSE:BDX) Stake Boosted by Abound Wealth Management

Abound Wealth Management lifted its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 96.0% during the second quarter, Holdings Channel reports. The firm owned 196 shares of the medical instruments supplier’s stock after buying an additional 96 shares during the period. Abound Wealth Management’s holdings in Becton, Dickinson and Company were worth $46,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in BDX. Ontario Teachers Pension Plan Board increased its position in Becton, Dickinson and Company by 3.8% in the 4th quarter. Ontario Teachers Pension Plan Board now owns 1,852,278 shares of the medical instruments supplier’s stock valued at $451,641,000 after acquiring an additional 68,509 shares during the period. Jennison Associates LLC lifted its holdings in Becton, Dickinson and Company by 4.9% in the first quarter. Jennison Associates LLC now owns 402,350 shares of the medical instruments supplier’s stock worth $99,562,000 after purchasing an additional 18,786 shares during the period. Norden Group LLC increased its stake in Becton, Dickinson and Company by 2,086.7% during the 1st quarter. Norden Group LLC now owns 51,934 shares of the medical instruments supplier’s stock valued at $12,853,000 after buying an additional 49,559 shares during the period. Franklin Street Advisors Inc. NC bought a new stake in shares of Becton, Dickinson and Company during the 1st quarter worth about $11,998,000. Finally, Avity Investment Management Inc. lifted its stake in shares of Becton, Dickinson and Company by 3.5% in the 1st quarter. Avity Investment Management Inc. now owns 162,687 shares of the medical instruments supplier’s stock worth $40,257,000 after acquiring an additional 5,527 shares during the period. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Price Performance

Shares of NYSE:BDX opened at $234.18 on Monday. The company has a market cap of $67.68 billion, a P/E ratio of 51.58, a price-to-earnings-growth ratio of 1.91 and a beta of 0.42. The company’s fifty day moving average is $234.71 and its two-hundred day moving average is $235.61. The company has a quick ratio of 1.36, a current ratio of 1.85 and a debt-to-equity ratio of 0.70. Becton, Dickinson and Company has a 12-month low of $218.75 and a 12-month high of $269.52.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.31 by $0.19. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. The firm had revenue of $4.99 billion during the quarter, compared to the consensus estimate of $5.08 billion. During the same period in the prior year, the business earned $2.96 EPS. The business’s revenue for the quarter was up 2.3% on a year-over-year basis. Equities analysts expect that Becton, Dickinson and Company will post 13.1 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, September 30th. Investors of record on Monday, September 9th will be given a dividend of $0.95 per share. This represents a $3.80 dividend on an annualized basis and a yield of 1.62%. The ex-dividend date is Monday, September 9th. Becton, Dickinson and Company’s payout ratio is presently 83.70%.

Analyst Ratings Changes

A number of research firms have weighed in on BDX. Raymond James cut their target price on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research report on Friday, August 2nd. StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. The Goldman Sachs Group assumed coverage on shares of Becton, Dickinson and Company in a research report on Thursday, May 30th. They issued a “buy” rating and a $274.00 price target on the stock. Evercore ISI reduced their price objective on shares of Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating for the company in a research report on Tuesday, July 2nd. Finally, Stifel Nicolaus raised their target price on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a report on Friday, July 26th. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $279.50.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.